Uranium-loaded apoferritin with antibodies attached: molecular design for uranium neutron-capture therapy.

AUTOR(ES)

Hainfeld, J F

RESUMO

A method is described to deliver 235U to tumors; the isotope would then be fissioned by incident neutrons, producing localized lethal radiation sufficient for therapy. Apoferritin was loaded with an average of approximately 800 238U atoms per molecule. Stability of the loaded apoferritin in solution was improved, so that only 8% loss of uranium occurred after 8 days at pH 7. Fab' antibody fragments were covalently attached to the uranium-loaded apoferritin, and the immunoreactivity of the conjugate was 92% of that for antibody alone. Such bio-uranium constructions should provide significant advantages over boronated antibodies to meet the requirements for clinical neutron-capture therapy.

Documentos Relacionados

• Homogeneous immunoconjugates for boron neutron-capture therapy: Design, synthesis, and preliminary characterization
• Neutron-capture therapy of human cancer: in vitro results on the preparation of boron-labeled antibodies to carcinoembryonic antigen.
• Model studies directed toward the boron neutron-capture therapy of cancer: boron delivery to murine tumors with liposomes.
• Neutron-capture therapy of human cancer: in vivo results on tumor localization of boron-10-labeled antibodies to carcinoembryonic antigen in the GW-39 tumor model system.
• Editorial: Neutron therapy.